Trial Information
Inclusion Criteria:
- Signed informed consent form
- Age ≥70 years
- Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1
- Histologically or cytologically confirmed lung cancer
- Did not receive bisphosphonate treatment
Exclusion Criteria:
- Appear relapse and metastasis
- receive other bisphosphonate treatment
- Active or uncontrolled infection
- Pregnant or lactating women
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Outcome Measure:
Progression-free survival(PFS)
Outcome Time Frame:
1 year
Safety Issue:
Yes
Principal Investigator
Wei Liu
Investigator Role:
Principal Investigator
Investigator Affiliation:
Hebei Tumor Hospital
Authority:
China: Food and Drug Administration
Study ID:
HBTH201
NCT ID:
NCT01737216
Start Date:
November 2012
Completion Date:
December 2016
Related Keywords:
- Lung Cancer
- Aged
- patients
- Lung Neoplasms